These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16460451)

  • 1. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
    Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH;
    J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors.
    Christopoulos CG
    Blood; 2003 Feb; 101(4):1655; author reply 1655. PubMed ID: 12560245
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
    Bougie DW; Wilker PR; Wuitschick ED; Curtis BR; Malik M; Levine S; Lind RN; Pereira J; Aster RH
    Blood; 2002 Sep; 100(6):2071-6. PubMed ID: 12200368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 6. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
    Abrams CS; Cines DB
    Curr Hematol Rep; 2004 Mar; 3(2):143-7. PubMed ID: 14965491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.
    Ali A; Patil S; Grady KJ; Schreiber TL
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):181-4. PubMed ID: 10642769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
    Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
    Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
    Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
    Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
    Vernon SM
    Cardiol Clin; 2001 May; 19(2):235-52, vi. PubMed ID: 11407108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
    Pang JT; Fort S; Della Siega A; Cohen EA
    J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
    J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ
    Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.